124 related articles for article (PubMed ID: 31771905)
1. The expression of versican and its role in pancreatic neuroendocrine tumors.
Gao H; Cheng Y; Chen Y; Luo F; Shao Y; Sun Z; Bai C
Pancreatology; 2020 Jan; 20(1):142-147. PubMed ID: 31771905
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of Versican Associated with Tumor Progression, Metastasis, and Poor Prognosis in Bladder Carcinoma.
Zhang Q; Wu J; Chen X; Zhao M; Zhang D; Gao F
Biomed Res Int; 2021; 2021():6949864. PubMed ID: 33604385
[TBL] [Abstract][Full Text] [Related]
3. Prediction of recurrence after surgery based on preoperative MRI features in patients with pancreatic neuroendocrine tumors.
Han S; Kim JH; Yoo J; Jang S
Eur Radiol; 2022 Apr; 32(4):2506-2517. PubMed ID: 34647178
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors for pancreatic neuroendocrine neoplasms (pNET) and the risk of small non-functioning pNET.
Lombardi M; De Lio N; Funel N; Sardella C; Russo D; Urbani C; Rossi G; Campani D; Martino E; Marcocci C; Boggi U; Bogazzi F
J Endocrinol Invest; 2015 Jun; 38(6):605-13. PubMed ID: 25501604
[TBL] [Abstract][Full Text] [Related]
5. Versican and vascular endothelial growth factor expression levels in peritoneal metastases from colorectal cancer are associated with survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Sluiter NR; de Cuba EM; Kwakman R; Meijerink WJ; Delis-van Diemen PM; Coupé VM; Beliën JA; Meijer GA; de Hingh IH; te Velde EA
Clin Exp Metastasis; 2016 Apr; 33(4):297-307. PubMed ID: 26873137
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic targeting of tumor-associated macrophages in pancreatic neuroendocrine tumors.
Krug S; Abbassi R; Griesmann H; Sipos B; Wiese D; Rexin P; Blank A; Perren A; Haybaeck J; Hüttelmaier S; Rinke A; Gress TM; Michl P
Int J Cancer; 2018 Oct; 143(7):1806-1816. PubMed ID: 29696624
[TBL] [Abstract][Full Text] [Related]
7. Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response.
Lamarca A; Barriuso J; Kulke M; Borbath I; Lenz HJ; Raoul JL; Meropol NJ; Lombard-Bohas C; Posey J; Faivre S; Raymond E; Valle JW
Br J Cancer; 2018 Jan; 118(2):181-188. PubMed ID: 29161241
[TBL] [Abstract][Full Text] [Related]
8. Molecular alterations in sporadic pancreatic neuroendocrine microadenomas.
Hadano A; Hirabayashi K; Yamada M; Kawanishi A; Takanashi Y; Kawaguchi Y; Nakagohri T; Nakamura N; Mine T
Pancreatology; 2016; 16(3):411-5. PubMed ID: 26905832
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of diagnosis, therapy and prognosis factors of 103 patients with pancreatic neuroendocrine tumors].
Luo Q; Liu YN; Ma HY; Li S; Huang JY; Li G; Jin G
Zhonghua Wai Ke Za Zhi; 2017 Oct; 55(10):755-759. PubMed ID: 29050176
[No Abstract] [Full Text] [Related]
10. Staging accuracy of MR for pancreatic neuroendocrine tumor and imaging findings according to the tumor grade.
Kim JH; Eun HW; Kim YJ; Han JK; Choi BI
Abdom Imaging; 2013 Oct; 38(5):1106-14. PubMed ID: 23728305
[TBL] [Abstract][Full Text] [Related]
11. Marital status is an independent prognostic factor for pancreatic neuroendocrine tumors patients: An analysis of the Surveillance, Epidemiology, and End Results (SEER) database.
Zhou H; Zhang Y; Song Y; Tan W; Qiu Z; Li S; Chen Q; Gao S
Clin Res Hepatol Gastroenterol; 2017 Sep; 41(4):476-486. PubMed ID: 28416359
[TBL] [Abstract][Full Text] [Related]
12. Tumor-infiltrating platelets predict postoperative recurrence and survival in resectable pancreatic neuroendocrine tumor.
Xu SS; Xu HX; Wang WQ; Li S; Li H; Li TJ; Zhang WH; Liu L; Yu XJ
World J Gastroenterol; 2019 Nov; 25(41):6248-6257. PubMed ID: 31749595
[TBL] [Abstract][Full Text] [Related]
13. ALCAM (CD166) expression as novel prognostic biomarker for pancreatic neuroendocrine tumor patients.
Tachezy M; Zander H; Marx AH; Gebauer F; Rawnaq T; Kaifi JT; Sauter G; Izbicki JR; Bockhorn M
J Surg Res; 2011 Oct; 170(2):226-32. PubMed ID: 21816425
[TBL] [Abstract][Full Text] [Related]
14. Versican enrichment predicts poor prognosis and response to adjuvant therapy and immunotherapy in gastric cancer.
Song J; Wei R; Huo S; Liu C; Liu X
Front Immunol; 2022; 13():960570. PubMed ID: 36203562
[TBL] [Abstract][Full Text] [Related]
15. Correlation of computed tomography imaging features and pathological features of 41 patients with pancreatic neuroendocrine tumors.
Utsumi M; Umeda Y; Takagi K; Takashi K; Nobuoka D; Yoshida R; Shinoura S; Sadamori H; Yagi T; Fujiwara T
Hepatogastroenterology; 2015; 62(138):441-6. PubMed ID: 25916078
[TBL] [Abstract][Full Text] [Related]
16. miR-590-3p Promotes Ovarian Cancer Growth and Metastasis via a Novel FOXA2-Versican Pathway.
Salem M; O'Brien JA; Bernaudo S; Shawer H; Ye G; Brkić J; Amleh A; Vanderhyden BC; Refky B; Yang BB; Krylov SN; Peng C
Cancer Res; 2018 Aug; 78(15):4175-4190. PubMed ID: 29748371
[TBL] [Abstract][Full Text] [Related]
17. Targeting of stromal versican by miR-144/199 inhibits multiple myeloma by downregulating FAK/STAT3 signalling.
Gupta N; Kumar R; Seth T; Garg B; Sharma A
RNA Biol; 2020 Jan; 17(1):98-111. PubMed ID: 31532704
[TBL] [Abstract][Full Text] [Related]
18. Versican and its associated molecules: potential diagnostic markers for multiple myeloma.
Gupta N; Khan R; Kumar R; Kumar L; Sharma A
Clin Chim Acta; 2015 Mar; 442():119-24. PubMed ID: 25623955
[TBL] [Abstract][Full Text] [Related]
19. Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours.
Dilz LM; Denecke T; Steffen IG; Prasad V; von Weikersthal LF; Pape UF; Wiedenmann B; Pavel M
Eur J Cancer; 2015 Jul; 51(10):1253-62. PubMed ID: 25935542
[TBL] [Abstract][Full Text] [Related]
20. PTCH 1 staining of pancreatic neuroendocrine tumor (PNET) samples from patients with and without multiple endocrine neoplasia (MEN-1) syndrome reveals a potential therapeutic target.
Gurung B; Hua X; Runske M; Bennett B; LiVolsi V; Roses R; Fraker DA; Metz DC
Cancer Biol Ther; 2015; 16(2):219-24. PubMed ID: 25482929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
